Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
TerSera Therapeutics real-world ziconotide data at ASPN 2025 shows rising guideline-based intrathecal pain therapy adoption
TerSera Therapeutics highlights real-world ziconotide prescribing trends at ASPN 2025, signaling growing guideline-aligned adoption in chronic pain management.
Genentech faces FDA setback for Columvi GemOx in second-line diffuse large B-cell lymphoma as SKYGLO trial becomes key to future U.S. expansion
Genentech’s Columvi GemOx sBLA faces FDA rejection in second-line DLBCL. Analysts await SKYGLO trial data for U.S. approval prospects. Learn more.
Why off-the-shelf CAR T therapies are attracting billion-dollar deals despite early-stage risks
Big pharma is betting billions on off-the-shelf CAR T therapies. Can allogeneic platforms overcome early-stage risks to transform cancer care?
Mallinckrodt secures Irish High Court approval for Endo merger, positioning scaled therapeutics leader for August 2025 closing
Mallinckrodt gains Irish High Court approval for its Endo merger, expected to close in August 2025. Analysts see scaled growth in specialty therapeutics.
Is Mereo BioPharma now a hidden EU rare disease play with Ultragenyx exposure?
Mereo BioPharma holds EU and UK rights to setrusumab. Can upcoming Phase 3 data make it a hidden rare disease winner in 2025?
Facioscapulohumeral muscular dystrophy market is set to expand through 2034 with gene therapy innovation and FDA acceleration
Facioscapulohumeral muscular dystrophy market to expand across 7MM by 2034, driven by gene therapy, rising diagnosis, and key drug launches from Roche, Avidity, and Epicrispr.
Can Biocon’s Kirsty become the Semglee of rapid-acting insulin in the US market?
Can Biocon Biologics repeat Semglee’s U.S. success with Kirsty? Find out if PBM coverage and pricing will fuel rapid adoption in the $1.9B insulin market.
Are global drugmakers shifting to Indian distribution alliances instead of building direct chronic care sales teams?
Global drugmakers are turning to Indian pharma partners for chronic care growth. Learn why alliances like Emcure–Sanofi are reshaping India’s diabetes drug market.
Is Imugene’s 17% stock slump an overreaction to dilution or a warning sign for CAR T investors?
Imugene shares fell 17% after a $37.5M raise, but can Fast Track and strong azer-cel data make the drop a buying opportunity for CAR T investors?
How does Amplia’s ACCENT trial compare to MPACT and POLO in pancreatic cancer response rates?
Amplia’s pancreatic cancer trial hits a 31% response rate, surpassing MPACT. Find out how it compares to POLO and what it means for future therapy options.